Alexander Adler, MD
Cardiovascular Disease · Peoria, ILNPI 1912929118
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 72.7% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2019 at $4,881 and has fallen 86.7% since, to $650 in 2025.
Across 81 payments — averaging $122.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$7K
- Boehringer Ingelheim$698
- Novartis$256
- Novo Nordisk$222
- Pfizer$181
- Abbott$170
- plus $1K from 20 others
Across 216 payments — averaging $6837.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Livanova USA, Inc.$481K
- Merck$259K
- Novartis$214K
- Eli Lilly$133K
- Boehringer Ingelheim$83K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$74K
- plus $234K from 7 others
What the payments were for
- Speaking & faculty fees$5,75058%
- Travel & lodging$9309%
- Food & beverage$3,19232%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 19 | $7,188 |
| Boehringer Ingelheim | 11 | $698 |
| Novartis | 11 | $256 |
| Novo Nordisk | 2 | $222 |
| Pfizer | 7 | $181 |
| Abbott | 4 | $170 |
| Abiomed | 1 | $146 |
| Medicure Pharma Inc. | 1 | $140 |
| Lilly USA, LLC | 1 | $121 |
| Edwards Lifesciences | 1 | $115 |
| Livanova USA, Inc. | 2 | $115 |
| Bayer | 2 | $76 |
| E.r. Squibb & Sons, L.L.C. | 2 | $74 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $61 |
| Scpharmaceuticals Inc. | 1 | $47 |
| Impulse Dynamics (USA) Inc. | 1 | $46 |
| Amgen | 2 | $42 |
| Johnson & Johnson | 2 | $38 |
| G Medical Diagnostic Services, Inc. | 1 | $29 |
| Cook Medical LLC | 1 | $28 |
| Merck | 1 | $24 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Mannkind Corporation | 1 | $15 |
| Infobionic, Inc | 1 | $13 |
| Medtronic | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,893 in reported general payments places this provider in the 80th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 590 | $553,107 |
| JardianceEmpagliflozin | 285 | $256,636 |
| XareltoRivaroxaban | 118 | $147,986 |
| EntrestoSacubitril/Valsartan | 75 | $98,620 |
| VeltassaPatiromer Calcium Sorbitex | 26 | $13,628 |
| FarxigaDapagliflozin Propanediol | 14 | $9,989 |
| BrilintaTicagrelor | 12 | $9,337 |
| Metoprolol Succinate | 573 | $8,099 |
| Bisoprolol Fumarate | 235 | $5,676 |
| Losartan Potassium | 513 | $4,137 |
| Furosemide | 561 | $4,085 |
| Bumetanide | 71 | $3,992 |
| Potassium Chloride | 200 | $3,812 |
| Atorvastatin Calcium | 482 | $3,706 |
| Carvedilol | 256 | $2,042 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $181 | $553,107590 claims |
| Boehringer IngelheimJardiance | $698 | $256,636285 claims |
| Johnson & JohnsonXarelto | $38 | $147,986118 claims |
| NovartisEntresto | $256 | $98,62075 claims |
| AstraZenecaFarxiga, Brilinta | $7,188 | $19,32626 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 932 cardiovascular disease providers in Illinois.
Other cardiovascular disease in Peoria
- Arvind Reddy DevanabandaPeoria$34K
- Sandeep NathanChicago$892K
- Alan BrownNaperville$858K
- Azmey MatariehElgin$762K
- Jay AlexanderBannockburn$744K
- Niraj VarmaMaywood$522K
- Boaz AvitallChicago$366K
- Akhil NarangChicago$363K
- Mark RabbatMaywood$363K
- Michael DavidsonChicago$317K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.